Apixaban to prevent stroke in patients with atrial fibrillation: a review

Benjamin E Peterson1, Sana M Al-Khatib2, Christopher B Granger2

  • 1Duke University Hospital, 2301 Erwin Road, Durham, NC 27710, USA.

Insights

Apixaban is a novel oral anticoagulant that effectively prevents stroke in atrial fibrillation patients. It offers superior stroke prevention compared to warfarin with a reduced risk of major bleeding.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Atrial fibrillation (AF) is a prevalent cardiovascular arrhythmia associated with significant morbidity and healthcare costs.
  • Stroke prevention is a critical management goal for patients with atrial fibrillation.
  • Novel oral anticoagulants (NOACs) targeting Factor IIa or Xa have transformed AF treatment.

Purpose of the Study:

  • To review the efficacy and tolerability of apixaban for stroke prevention in atrial fibrillation.
  • To assess the generalizability of apixaban trial findings to broader patient populations.

Main Methods:

  • Review of data from the AVERROES and ARISTOTLE clinical trials.
  • Analysis of secondary trial data and subgroup findings.
  • Evaluation of apixaban's safety and effectiveness profile.

Main Results:

  • Apixaban demonstrated superior stroke prevention compared to warfarin in the general AF population.
  • Apixaban was associated with a significantly lower risk of major bleeding than warfarin.
  • These benefits were observed across various high-risk patient subgroups.

Conclusions:

  • Apixaban is a highly effective and safe anticoagulant for stroke prevention in atrial fibrillation.
  • Apixaban offers advantages over warfarin in both efficacy and safety, including in high-risk populations.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
455
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
567
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
629